NVS240920C125000
- 0.35
- +0.01+2.94%
Novartis AG Newsroom
Top Gap Ups and Downs on Friday: BABA, PDD, INTU and More
Top Gap Ups and Downs on Thursday: NVO, UL, ITUB and More
Tectonic Draws Bullish View at Wells Fargo on Lead Asset
Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding
Top Gap Ups and Downs on Wednesday: AXP, BHP, TJX and More
Novartis AG Falls Wednesday
Top Gap Ups and Downs on Tuesday: BAC, BABA, PANW and More
BioCentury to Host Grand Rounds in Nashville: A Premier Gathering of Drug Development Thought Leaders at the Interface of Academia and Industry
FTC Says FDA Biosimilar Guidance Would Increase Competition, Lead to Lower Prices
Top Gap Ups and Downs on Monday: BBVA, STLA, VALE and More
Novartis AG Rises Monday
Novartis Well on Track to Achieve Guidance -- Market Talk
J&J, Roche Come Out on Top in S&P Ratings of Strongest Pharma Companies
Trending Stocks This Week as U.S. Equities Notch Their Best Week of 2024
Top Gap Ups and Downs on Friday: SONY, IBN, DEO and More
Top Gap Ups and Downs on Thursday: WMT, CSCO, MUFG and More
Medicare Negotiates Lower Prices for 10 High-cost Drugs
Big Pharma: The Government Revealed Its List of Negotiated Drug Prices. Here Are the Reactions.
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Negotiations on pharmaceutical prices in the United States have resulted in significant price reductions for ten key medications with the highest reduction approaching 80%.
According to the inflation reduction bill of the Biden administration, the final negotiated prices of the top 10 pharmaceuticals in Part D of federal medical insurance have been determined and announced.